Menu Close

GLP-1 weight-loss and diabetes drugs may dominate headlines and group health budgets, but they barely register in workers’ compensation costs, according to new data from the National Council on Compensation Insurance (NCCI). In the latest installment of its “Asked & Answered” series, published November 10, 2026, NCCI reports that GLP-1 drugs accounted for only about 0.02% of workers’ compensation medical spending in 2025, and the bureau says it does not expect them to become a significant loss driver.

The “Asked & Answered” series responds to questions submitted by stakeholders, using NCCI data to explain what trends mean for the workers’ compensation system. This edition, written by Geena Baldi, takes on two questions: how much GLP-1 medications are showing up in comp claims, and where the medical share of total losses stands today.

On the first question, NCCI’s Medical Data Call shows roughly $1.9 million paid for GLP-1 drugs in 2025, against about $9.3 billion in total workers’ compensation medical payments. Claims involving GLP-1s likewise made up about 0.02% of claim counts.

That small number has been growing. NCCI dates the starting point to 2021, when the U.S. Food and Drug Administration first approved semaglutide for chronic weight management. Since then, GLP-1 payments in workers’ compensation have grown at an average annual rate of nearly 40%, rising from 0.01% of medical spend in 2021 to 0.02% in 2025. According to NCCI, that growth reflects more claims involving the drugs rather than higher prices: the average amount paid per transaction has held steady at roughly $1,200 to $1,300.

NCCI cautions that with use this limited, broad generalizations about GLP-1 claims are difficult. The bureau classified diagnoses and body systems using the top two ICD-10 codes on each medical bill, and it examined whether the drugs were being used to help injured workers lose weight before surgery (defining major surgery as a non-injection service with a 90-day global follow-up period under CMS rules, or a procedure involving spinal neurostimulators). Its key finding: the data shows no meaningful use of GLP-1s for pre-surgical weight loss.

Looking ahead, NCCI says it does not anticipate GLP-1s becoming a significant cost driver, largely because obesity is typically not a compensable injury. The bureau says it will keep monitoring the drugs and report further insights as warranted.

The second part of the article updates a metric NCCI first presented at its Annual Insights Symposium in 2024 and 2025: the share of workers’ compensation losses attributable to medical costs. NCCI’s preliminary estimate puts the medical share for Accident Year 2025 at 53%, unchanged from Accident Year 2024. The share has been roughly flat for at least two decades, peaking at 56.6% in Accident Year 2016 and drifting down since.

NCCI attributes the recent decline to indemnity losses growing faster than medical losses, consistent with its finding that wage growth has recently outpaced medical inflation as measured by its Workers Compensation Weighted Medical Price Index (see NCCI’s Medical Inflation Insights). Because indemnity benefits are tied to wages, faster wage growth pushes up the indemnity side of the ledger. NCCI notes that wage projections from the U.S. Bureau of Labor Statistics and medical price projections from CMS suggest the pattern will continue. Accident Year 2026 estimates are still developing, but if wages keep outpacing medical prices, NCCI says the medical share could remain near 2024–2025 levels or decline.

NCCI flags several caveats for the medical-share figures. They are based on NCCI Financial Call data developed to ultimate, covering data through December 31, 2024, with 2025 figures preliminary and valued as of December 31, 2025. The data excludes large-deductible policies and COVID-19 claims through July 1, 2023, and covers all states where NCCI provides ratemaking services, with Texas excluded through 2010 and West Virginia through 2014. The methodology mirrors the approach in NCCI’s most recent rate and loss cost filings.

For employers and insurers, the takeaway is twofold: the GLP-1 boom that is straining group health plans has so far had a negligible effect on comp medical costs, and the long-standing medical-versus-indemnity split remains stable, with wage growth, not medical inflation, currently doing more to move the needle. Stakeholders can submit questions for future installments to NCCI at INSIGHTS@ncci.com.